Gene Name	Entrez ID	Drug Name	Chembl ID	Interaction Types	Sources	publications
TYMP	1890	TIPIRACIL	CHEMBL235668		DrugBank
TYMP	1890	DOXIFLURIDINE	CHEMBL1130		NCI	11956613
TYMP	1890	TIPIRACIL HYDROCHLORIDE	CHEMBL65375	inhibitor	ChemblInteractions
TYMP	1890	SULFASALAZINE	CHEMBL421		NCI	15269287
TYMP	1890	MYCOPHENOLIC ACID	CHEMBL866		NCI	12711006
TYMP	1890	FLUOROURACIL	CHEMBL185		PharmGKB, NCI	11205264

Gene Name	Variant	Alleles	Chemical	Phenotype Category	Significance	Notes	Sentence	Publications	Annotation ID
TYMP	rs11479	AA + AG	capecitabine	dosage	yes	Clinical data about adverse events were collected from patient records and laboratory charts for 12 weeks after the initiation of therapy. Delays or reductions in the administration of 5'FU or capecitabine due to adverse events were recorded as primary outcomes, and grade 3,4,5 adverse events were analyzed as secondary outcomes. "Dose" here refers to dose modification.	Genotypes AA + AG is associated with dose of capecitabine or fluorouracil in people with Colorectal Neoplasms as compared to genotype GG.	24167597	1184471936
TYMP	rs11479	AA + AG	bevacizumab	efficacy	no	No significant association with response, progression-free survival or overall survival was found for this variant. Please note that alleles have been complemented to the plus chromosomal strand.	Genotypes AA + AG are not associated with response to bevacizumab, capecitabine, cisplatin, docetaxel, epirubicin, oxaliplatin or trastuzumab in people with Stomach Neoplasms as compared to genotype GG.	27995989	1448568284